Diabetes impacts hundreds of thousands of Australians, necessitating daily management that often involves multiple insulin injections. While injectable insulin is life-saving, it can be cumbersome and distressing for patients. Frequent injections can lead to discomfort, inconvenience, and can be a constant reminder of their chronic condition.

Afrezza, an inhaled insulin, offers a revolutionary alternative to traditional injection methods. Unlike injectable insulin, Afrezza provides a quicker onset of action, mimicking the natural insulin response. It allows for easier blood sugar management and improves the overall quality of life for those who must frequently rely on insulin. Its availability in overseas markets such as the United States has seen positive outcomes and satisfaction among diabetic patients.

The Therapeutic Goods Administration (TGA) must prioritize the assessment process for Afrezza to make this innovative treatment option available to Australian diabetes patients. Fast-tracking its approval would mean quicker access to a treatment that has the potential to change lives for the better. Many Australians are on waiting lists, hoping for a chance to integrate this modern solution into their routines.

Statistics show that nearly 1.8 million Australians are living with diabetes, and with this number steadily climbing, the need for an alternative, less invasive insulin delivery method becomes more pressing. It's crucial to provide Australians with every available method to manage their diabetes effectively and comfortably.

By signing this petition, you support the call for the TGA to evaluate, approve, and expedite the introduction of Afrezza inhaled insulin in Australia. Let’s work together to ensure all Australians have access to life-changing diabetic care alternatives.